Neurodegeneration and peroxidases

Neurobiology of Aging

Volumn 30, Issue 7, 2009, Pages 1011-1025

  Everse, Johannes ^a   Coates, Penelope W ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; Amyotrophic lateral sclerosis; Apoptosis; Biochemistry of neurodegeneration; Cytochrome c; Neurodegeneration; Oxidative damage; Parkinson's disease; Peroxidases

Indexed keywords

4 (4 HYDROXYANILINO) 6,7 DIMETHOXYQUINAZOLINE; ACETYLCYSTEINE; ACETYLSALICYLIC ACID; AMYLOID BETA PROTEIN; APOMORPHINE; CELECOXIB; CLIOQUINOL; COPPER ZINC SUPEROXIDE DISMUTASE; CREATINE; CURCUMIN; CYCLOOXYGENASE 2; CYTOCHROME C; CYTOCHROME C OXIDASE; CYTOCHROME C PEROXIDASE; DEFEROXAMINE MESYLATE; DOPAMINE; GLUTATHIONE; IBUPROFEN; INOSITOL; LEVODOPA; LIPID; MINOCYCLINE; MYELOPEROXIDASE; PARGYLINE; PEROXIDASE; PEROXYNITRITE; SELEGILINE; SUICIDE SUBSTRATE;

AEROBIC METABOLISM; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; APOPTOSIS; BIOCHEMISTRY; BRAIN DEGENERATION; CATALYSIS; CATALYST; DEGENERATIVE DISEASE; DISEASE COURSE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYMOLOGY; HUMAN; NERVE CELL; NERVE DEGENERATION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN FUNCTION; REVIEW;

APOPTOSIS; CENTRAL NERVOUS SYSTEM; LIPID PEROXIDATION; NERVE TISSUE PROTEINS; NEURODEGENERATIVE DISEASES; OXIDATION-REDUCTION; OXIDATIVE STRESS; PEROXIDASES; SIGNAL TRANSDUCTION;

EID: 65649126821     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2007.10.007     Document Type: Review

References (162)

1. Agil A., Duran R., Barrero F., Morales B., Arauzo M., Alba F., Miranda M.T., Prieto I., Ramirez M., and Vives F. Plasma lipid peroxidation in sporadic Parkinson's disease. Role of the l-dopa. J. Neurol. Sci. 240 (2006) 31-36
2. Akama K.T., Albanese C., Pestell R.G., and Van Eldik L.J. Amyloid beta-peptide stimulates nitric oxide production in astrocytes through an NkκB-dependent mechanism. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 5795-5800
3. Alano C.C., Kauppinen T.M., Valls A.V., and Swanson R.A. Minocycline inhibits poly(ADP-ribose) polymerase-1 at nanomolar concentrations. Proc. Natl. Acad. Sci. U.S.A. 103 (2006) 9685-9690
4. Arnhold J., Furtmüller P.G., Regelsberger G., and Obinger C. Redox properties of the couple compound I/native enzyme of myeloperoxidase and eosinophil peroxidase. Eur. J. Biochem. 268 (2001) 5124-5148
5. Arnhold J., Furtmüller P.G., and Obinger C. Redox properties of myeloperoxidase. Redox Rep. 8 (2003) 179-186
6. Atamna H. Heme binding to amyloid-beta peptide: mechanistic role in Alzheimer's disease. J. Alzheimers Dis. 10 (2006) 255-266
7. Atamna H., and Boyle K. Amyloid-β peptide binds with heme to form a peroxidase: relationship to the cytopathologies of Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 103 (2006) 3381-3386
8. Aubin N., Curet O., Deffois A., and Carter C. Aspirin and salicylate protect against MPTP-induced dopamine depletion in mice. J. Neurochem. 71 (1998) 1635-1642
9. Bains J.S., and Shaw C.A. Neurodegenerative disorders in humans: the role of glutathione in oxidative stress-mediated neuronal death. Brain Res. Brain Res. Rev. 25 (1997) 335-358
10. Ballard P.A., Tetrud J.W., and Langston J.W. Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): seven cases. Neurology 35 (1985) 949-956
11. Barcia C., Sanchez Bahillo A., Fernandez-Villalba E., Bautista V., Poza Y., Poza M., Fernandez-Barreiro A., Hirsch E.C., and Herrero M.T. Evidence of active microglia in substantia nigra pars compacta of parkinsonian monkeys 1 year after MPTP exposure. Glia 46 (2004) 402-409
12. Barone F.C., Hillegass L.M., Price W.J., White R.F., Lee E.V., Feuerstein G.Z., Sarau H.M., Clark R.K., and Griswold D.E. Polymorphonuclear leukocyte infiltration into cerebral focal ischemic tissue: myeloperoxidase activity assay and histologic verification. J. Neurosci. Res. 29 (1991) 336-345
13. Bartov O., Sultana R., Butterfield D.A., and Atlas D. Low molecular weight thiol amides attenuate MAPK activity and protect primary neurons from Abeta(1-42) toxicity. Brain Res. 1069 (2006) 198-206
14. Batthyany C., Souza J.M., Duran R., Cassina A., Cervenansky C., and Radi R. Time course and site(s) of cytochrome c tyrosine nitration by peroxynitrite. Biochemistry 44 (2005) 8038-8046
15. Beal F., and Lang A. The proteasomal inhibition model of Parkinson's disease: "Boon or bust"?. Ann. Neurol. 60 (2006) 158-161
16. Beal M.F. Mitochondria take center stage in aging and neurodegeneration. Ann. Neurol. 58 (2005) 495-505
17. Beckman J.S., and Crow J.P. Pathological implications of nitric oxide, superoxide and peroxynitrite formation. Biochem. Soc. Trans. 21 (1993) 330-334
18. Belikova N.A., Vladimirov Y.A., Osipov A.N., Kapralov A.A., Tyurin V.A., Potapovich M.V., Basova L.V., Peterson J., Kurnikov I.V., and Kagan V.E. Peroxidase activity and, structural transitions of cytochrome c bound to cardiolipin-containing membranes. Biochemistry 45 (2006) 4998-5009
19. Ben-Shachar D., Eshel G., Finberg J.P.M., and Youdim M.B.H. The iron chelator desferrioxamine (Desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal dopamine neurons. J. Neurochem. 56 (1991) 1441-1444
20. Bernardo A., Gasparini L., Ongini E., and Minghetti L. Dynamic regulation of microglial functions by the non-steroidal anti-inflammatory drug NCX 2216: implications for chronic treatments of neurodegenerative diseases. Neurobiol. Dis. 22 (2005) 25-32
21. Blum D., Chtarto A., Tenenbaum L., Brotchi J., and Levivier M. Clinical potential of minocycline for neurodegenerative disorders. Neurobiol. Dis. 17 (2004) 359-366
22. Bobba A., Atlante A., Giannattasio S., Sgaramella G., Calissano P., and Marra E. Early release and subsequent caspase-mediated degradation of cytochrome c in apoptotic cerebellar granule cells. FEBS Lett. 457 (1999) 126-130
23. Bogdanov M.B., Ramos L.E., Xu Z., and Beal M.F. Elevated "hydroxyl radical" generation in vivo in an animal model of amyotrophic lateral sclerosis. J. Neurochem. 71 (1998) 1321-1324
24. Bonini M.G., Radi R., Ferrer-Sueta G., Ferreira A.M., and Augusto O. Direct EPR detection of the carbonate radical anion produced from peroxynitrite and carbon dioxide. J. Biol. Chem. 274 (1999) 10806-19802
25. Bonini M.G., Fernandes D.C., and Augusto O. Albumin oxidation to diverse radicals by the peroxidase activity of Cu-Zn-superoxide dismutase in the presence of bicarbonate or nitrite: diffusible radicals produce cysteinyl and solvent-exposed and -unexposed tyrosyl radicals. Biochemistry 43 (2004) 344-351
26. Bruijn L.I., Miller T.M., and Cleveland D.W. Unraveling the mechanisms involved in motor neuron degeneration in ALS. Annu. Rev. Neurosci. 27 (2004) 723-749
27. 2: relevance to redox signalling in apoptosis. Biochem. Soc. Symp. 71 (2004) 97-106
28. Burns R.S., LeWitt P.A., Ebert M.H., Pakkenberg H., and Kopin I.J. The clinical syndrome of striatal dopamine deficiency. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). New Engl. J. Med. 312 (1985) 1418-1421
29. Casoni F., Basso M., Massignan T., Gianazza E., Cheroni C., Salmona M., Bendotti C., and Bonetto V. Protein nitration in a mouse model of familial amyotrophic lateral sclerosis: possible multifunctional role in the pathogenesis. J. Biol. Chem. 280 (2005) 16295-16304
30. Caspersen C., Wang N., Yao J., Sosunov A., Chen X., Lustbader J.W., Xu H.W., Stern D., McKhann G., and Yan S.D. Mitochondrial Abeta: a potential focal point for neuronal metabolic dysfunction in Alzheimer's disease. FASEB J. 19 (2005) 2040-2041
31. Cassina A.M., Hodara R., Souza J.M., Thomson L., Castro L., Ischiropoulos H., Freeman B.A., and Radi R. Cytochrome c nitration by peroxynitrite. J. Biol. Chem. 275 (2000) 21409-21415
32. Castro L., Eiserich J.P., Sweeney S., Radi R., and Freeman B.A. Cytochrome c: a catalyst and target of nitrite-hydrogen peroxide-dependent protein nitration. Arch. Biochem. Biophys. 421 (2004) 99-107
33. Choi J., Levey A.I., Weintraub S.T., Rees H.D., Gearing M., Chin L.-S., and Li L. Oxidative modifications and down-regulation of ubiquitin carboxyl-terminal hydrolase L1 associated with idiopathic Parkinson's and Alzheimer's diseases. J. Biol. Chem. 279 (2004) 13256-13264
34. Choi J., Rees H.D., Weintraub S.T., Levey A.I., Chin L.S., and Li L. Oxidative modifications and aggregation of Cu,Zn-superoxide dismutase associated with Alzheimer and Parkinson diseases. J. Biol. Chem. 280 (2005) 11648-11655
35. Choi D.-K., Pennathur S., Perier C., Tieu K., Teismann P., Wu D.-C., Jackson-Lewis V., Vila M., Vonsattel J.-P., Heinecke J.W., and Przedborski S. Ablation of the inflammatory enzyme myeloperoxidase mitigates features of Parkinson's disease in mice. J. Neurosci. 25 (2005) 6594-6600
36. Colzi A., Turner K., and Lees A.J. Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 64 (1998) 573-576
37. Coma M., Guix F.X., Uribesalgo I., Espuna G., Sole M., Andreu D., and Munoz F.J. Lack of oestrogen protection in amyloid-mediated endothelial damage due to protein nitrotyrosination. Brain 128 (2005) 1613-1621
38. Combs S.H., Morgan C.D., and Everse J. Antitumor activity of an immobilized peroxidase system against murine Ehrlich ascites is mediated by the immune system. Proc. Soc. Exp. Biol. Med. 204 (1993) 306-311
39. Davis G.C., Williams A.C., Markey S.P., Ebert M.H., Caine E.D., Reichert C.M., and Kopin I.J. Chronic parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatry Res. 1 (1979) 249-254
40. Date I., Felten D.L., and Felten S.Y. Long-term effect of MPTP in the mouse brain in relation to aging: neurochemical and immunocytochemical analysis. Brain Res. 519 (1990) 266-276
41. Denicola A., Souza J.M., and Radi R. Diffusion of peroxynitrite across erythrocyte membranes. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 3566-3571
42. Drachman D.B., Frank K., Dykes-Hoberg M., Teismann P., Almer G., Przedborski S., and Rothstein J.D. Cyclooxygenase 2 inhibition protects motor neurons and prolongs survival in a transgenic mouse model of ALS. Ann. Neurol. 52 (2002) 771-778
43. Eidelberg E., Brooks B.A., Morgan W.W., Walden J.G., and Kokemoor R.H. Variability and functional recovery in the N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of parkinsonism in monkeys. Neuroscience 18 (1986) 817-822
44. Everse J. The structure of heme proteins Compounds I and II: some misconceptions. Free Radic. Biol. Med. 24 (1998) 1338-1346
45. Everse J., and Coates P.W. The cytotoxic activity of lactoperoxidase: enhancement and inhibition by neuroactive compounds. Free Radic. Biol. Med. 37 (2004) 839-849
46. Everse J., and Coates P.W. Role of peroxidases in Parkinson's disease: a hypothesis. Free Radic. Biol. Med. 38 (2005) 1296-1310
47. Everse J., Ginsburgh C.L., and Kaplan N.O. Immobilized enzymes in biochemical analysis. In: Glick D. (Ed). Methods of Biochemical Analysis vol. 25 (1979), John Wiley and Sons, New York 136-201
48. Everse J., Johnson M.C., and Marini M.A. Peroxidative activities of hemoglobin and hemoglobin derivatives. In: Everse J., Vandegriff K.D., and Winslow R.M. (Eds). Hemoglobins; Biochemical and Analytical Methods (Methods in Enzymology) vol. 231 (1994), Academic Press, San Diego 547-561
49. Everse K.E., Lin H., Stuyt E.L., Brady J.C., Buddingh F., and Everse J. Antitumour activity of peroxidases. Br. J. Cancer 51 (1985) 743-746
50. Familian A., Boshuizen R.S., Eikelenboom P., and Veerhuis R. Inhibitory effect of minocycline on amyloid beta fibril formation and human microglial activation. Glia 53 (2006) 233-240
51. Fiskum G., Starkov A., Polster B.M., and Chinopoulos C. Micochondrial mechanisms of neural cell death and neuroprotective interventions in Parkinson's disease. Ann. N Y Acad. Sci. 991 (2003) 111-119
52. Forno L.S., DeLanney L.E., Irwin I., and Langston J.W. Similarities and differences between MPTP-induced parkinsonism and Parkinson's disease. Neuropathologic considerations. Adv. Neurol. 60 (1993) 600-608
53. Gao H.-M., Liu B., Zhang W., and Hong J.-S. Critical role of microglial NADPH oxidase-derived free radicals in the in vitro MPTP model of Parkinson's disease. FASEB J. 17 (2003) 1954-1956
54. Garcia-Allano, M., Borrelli, L.A., Rozkalne, A., Hyman, B.T., Bacskai, B.J., 2007. Curcumin labels amyloid pathology in vivo, disrupts existing plaques, and partially restores distorted neurites in an Alkzheimer mouse model. J. Neurochem. doi:10.1111/j.1471-4159.2007.04613.x.
55. Giovannini M.G., Scali C., Prosperi C., Bellucci A., Pepeu G., and Casamenti F. Experimental brain inflammation and neurodegeneration as model of Alzheimer's disease: protective effects of selective COX-2 inhibitors. Int. J. Immunopathol. Pharmacol. 16 2 Suppl. (2003) 31-40
56. - toward NADH. Chem. Res. Toxicol. 13 (2000) 736-741
57. Good P.F., Werner P., Hsu A., Olanow C.W., and Perl D.P. Evidence of neuronal oxidative damage in Alzheimer's disease. Am. J. Pathol. 149 (1996) 21-28
58. Green P.S., Mendez A.J., Jacobs J.S., Crowley J.R., Growdon W., Hyman B.T., and Heinecke J.W. Neuronal expression of myeloperoxidase is increased in Alzheimer's disease. J. Neurochem. 90 (2004) 724-733
59. Grisham M.B., Perez V.J., and Everse J. Neuromelanogenic and cytotoxic properties of canine brainstem peroxidase. J. Neurochem. 48 (1987) 876-882
60. Guegan C., Vila M., Rosoklija G., Hays A.P., and Przedborski S. Recruitment of the mitochondrial-dependent apoptotic pathway in amyotrophic lateral sclerosis. J. Neurosci. 21 (2001) 6569-6576
61. Gunther M.R., Hsi L.C., Curtis J.F., Gierse J.K., Marnett L.J., Eling T.E., and Mason R.P. Nitric oxide trapping of the tyrosyl radical of prostaglandin H synthase-2 leads to tyrosine iminoxyl radical and nitrotyrosine formation. J. Biol. Chem. 272 (1997) 17086-17090
62. Gurney M.E. The use of transgenic mouse models of amyotrophic lateral sclerosis in preclinical drug studies. J. Neurol. Sci. 152 (1997) S67-S73
63. + induces NADH dependent superoxide formation and enhances NADH dependent lipid peroxidation in bovine heart submitochondrial particles. Biochem. Biophys. Res. Commun. 170 (1990) 1049-1055
64. Hashimoto M., Takeda A., Hsu L.J., Takenouchi T., and Masliah E. Role of cytochrome c as a stimulator of α -synuclein aggregation in Lewy body disease. J. Biol. Chem. 274 (1999) 28849-28852
65. Heidenreich K.A. Molecular mechanisms of neuronal cell death. Ann. N Y Acad. Sci. 991 (2003) 237-250
66. Henderson Jr. W.R. Eosinophil peroxidase: occurrence and biological function. In: Everse J., Everse K.E., and Grisham M.B. (Eds). Peroxidases in Chemistry and Biology vol. 1 (1991), CRC Press, Boca Raton 105-121
67. Hirsch E.C., Breidert T., Rousselet E., Hunot S., Hartmann A., and Michel P.P. The role of glial reaction and inflammation in Parkinson's disease. Ann. N Y Acad. Sci. 991 (2003) 214-228
68. Hoozemans J.J.M., Rozemuller A.J.M., Janssen I., De Groot C.J.A., Veerhuis R., and Eikelenboom P. Cyclooxygenase expression in microglia and neurons in Alzheimer's disease and control brain. Acta Neuropathol. 101 (2001) 2-8
69. Hoozemans J.J., Bruckner M.K., Rozemuller A.J., Veerhuis R., Eikelenboom P., and Arendt T. Cyclin D1 and cyclin E are co-localized with cyclooxygenase 2 (COX-2) in pyramidal neurons in Alzheimer disease temporal cortex. J. Neuropathol. Exp. Neurol. 61 (2002) 678-688
70. Huber A., Stuchbury G., Burkle A., Burnell J., and Munch G. Neuroprotective therapies for Alzheimer's disease. Curr. Pharm. Des. 12 (2006) 705-717
71. Jang B., and Han S. Biochemical properties of cytochrome c nitrated by peroxynitrite. Biochimie 88 (2006) 53-58
72. Jiang J., Serinkan B.F., Tyurina A.A., Borisenko G.G., Mi Z., Robbins P.D., Schroit A.J., and Kagan V.E. Peroxidation and externalization of phosphatidylserine associated with release of cytochrome c from mitochondria. Free Radic. Biol. Med. 35 (2003) 814-825
73. Johannessen J.N., Chiueh C.C., Burns R.S., and Markey S.P. Differences in the metabolism of MPTP in the rodent and primate parallel differences in sensitivity to its neurotoxic effect. Life Sci. 36 (1985) 219-224
74. Johnston J.A., Dalton M.J., Gurney M.E., and Kopito R.R. Formation of high molecular weight complexes of mutant Cu-Zn superoxide dismutase in a mouse model for familial amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 12571-12576
75. Jolivalt C., Leininger-Muller B., Drozdz R., Naskalski J.W., and Siest G. Apolipoprotein E is highly susceptible to oxidation by myeloperoxidase, an enzyme present in the brain. Neurosci. Lett. 210 (1996) 61-64
76. Jordan J., Cena V., and Prehn J.H. Mitochondrial control of neuron death and its role in neurodegenerative disorders. J. Physiol. Biochem. 59 (2003) 129-141
77. Kagan V.E., Tyurina Y.Y., Bayir H., Chu C.T., Kapralov A.A., Vlasova I.I., Belikova N.A., Tyurin V.A., Amoscato A., Epperly M., Greenberger J., Dekosky S., Shvedova A.A., and Jiang J. The "pro-apoptotoc genies" get out of mitochondria: oxidative lipidomics and redox activity of cytochrome c/cardiolipin complexes. Chem. Biol. Interact. 163 (2006) 15-28
78. Kang J.H., and Eum W.S. Enhanced oxidative damage by the familial amyotrophic lateral sclerosis-associated Cu,Zn-superoxide dismutase mutants. Biochim. Biophys. Acta 1524 (2000) 162-170
79. Kirkinezos I.G., Bacman S.R., Hernandez D., Oca-Cossio J., Arias L.J., Perez-Pinzon M.A., Bradley W.G., and Moraes C.T. Cytochrome c association with the inner mitochondrial membrane is impaired in the CNS of G93A-SOD1 mice. J. Neurosci. 25 (2005) 164-172
80. Klebanoff S.J. Myeloperoxidase: occurrence and biological function. In: Everse J., Everse K.E., and Grisham M.B. (Eds). Peroxidases in Chemistry and Biology vol. 1 (1991), CRC Press, Boca Raton 1-35
81. Klivenyi P., Ferrante R.J., Matthews R.T., Bogdanov M.B., Klein A.M., Andreassen O.A., Mueller G., Wermer M., Kaddurah-Daouk R., and Beal M.F. Neuroprotective effects of creatine in a transgenic animal model of amylotrophic lateral sclerosis. Nat. Med. 5 (1999) 347-350
82. Kordower J.H., Kanaan N.M., Chu Y., Suresh Babu R., Stansell III J., Terpstra B.T., Sortwell C.E., Steece-Collier K., and Collier T.J. Failure of proteasome inhibitor administration to provide a model of Parkinson's disease in rats and monkeys. Ann. Neurol. 60 (2006) 264-268
83. Kostic V., Jackson-Lewis V., De Bilbao F., Dubois-Dauphin M., and Przedborski S. Bcl-2: prolonging life in a transgenic mouse model of familial amyotrophic lateral sclerosis. Science 277 (1997) 559-562
84. Kriz J., Nguyen M.D., and Julien J.P. Minocycline slows disease progression in a mouse model of amyotrophic lateral sclerosis. Neurobiol. Dis. 10 (2002) 268-278
85. Langston J.W., Ballard P., Tetrud J.W., and Irwin I. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219 (1983) 979-980
86. Langston J.W., Forno L.S., Tetrud J., Reeves A.G., Kaplan J.A., and Karluk D. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann. Neurol. 46 (1999) 598-605
87. 2. Implications for oxidative stress during apoptosis. J. Biol. Chem. 278 (2003) 29410-29419
88. LeBlanc A.C. The role of apoptotic pathways in Alzheimer's disease neurodegeneration and cell death. Curr. Alzheimer Res. 2 (2005) 389-402
89. Li M., Ona V.O., Guegan C., Chen M., Jackson-Lewis V., Andrews L.J., Olszewski A.J., Stieg P.E., Lee J.P., Przedborski S., and Friedlander R.M. Functional role of caspase-1 and caspase-3 in an ALS transgenic mouse model. Science 288 (2000) 335-339
90. Linton M.F., and Fazio S. Cyclooxygenase-2 and inflammation in atherosclerosis. Curr. Opin. Pharmacol. 4 (2004) 116-123
91. Liu H., Wang H., Shenvi S., Hagen T.M., and Liu R.M. Glutathione metabolism during aging and in Alzheimer's disease. Ann. N Y Acad. Sci. 1019 (2004) 346-349
92. Lymar S.V., Jiang Q., and Hurst J.K. Mechanism of carbon dioxide-catalyzed oxidation of tyrosine by peroxynitrite. Biochemistry 35 (1996) 7855-7861
93. Maihöfner C., Probst-Cousin S., Bergmann M., Neuhuber W., Neundörfer B., and Heuss D. Expression and localization of cyclooxygenase-1 and -2 in human sporadic amyotrophic lateral sclerosis. Eur. J. Neurosci. 18 (2003) 1527-1534
94. Manfredi G., and Xu Z. Mitochondrial dysfunction and its role in motor neuron degeneration in ALS. Mitochondrion 5 (2005) 77-87
95. Markey S.P., Johannessen J.N., Chiueh C.C., Burns R.S., and Herkendam M.A. Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism. Nature 311 (1984) 464-467
96. McFaul S.J., and Everse J. Continuous assay for cytolytic activity. In: Di Sabato G., and Everse J. (Eds). Immunochemical Techniques. Part J. Phagocytosis and Cell-Mediated Cytotoxicity (Methods in Enzymology) vol. 132 (1986), Academic Press, San Diego 491-498
97. McGeer P.L., and McGeer E.G. Inflammatory processes in amyotrophic lateral sclerosis. Muscle Nerve 26 (2002) 459-470
98. McGeer P.L., and McGeer E.G. NSAIDs and Alzheimer's disease: epidemiological, animal model and clinical studies. Neurobiol. Aging 28 (2007) 639-647
99. McGeer P.L., Itagaki S., Boyes B.E., and McGeer E.G. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 38 (1988) 1285-1291
100. McLaurin J., Golomb R., Jurewicz A., Antel J.P., and Fraser P.E. Inositol stereoisomers stabilize oligomeric aggregate of Alzheimer amyloid beta peptide and inhibit abeta-induced toxicity. J. Biol. Chem. 275 (2000) 18495-18502
101. McNaught K.S., Perl D.P., Brownell A.L., and Olanow C.W. Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease. Ann. Neurol. 56 (2004) 149-162
102. McNaught K.S., and Olanow C.W. Proteasome inhibitor-induced model of Parkinson's disease. Ann. Neurol. 60 (2006) 243-247
103. Mitsumoto Y., Watanabe A., Mori A., and Koga N. Spontaneous regeneration of nigrostriatal dopaminergic neurons in MPTP-treated C57BL/6 mice. Biochem. Biophys. Res. Commun. 248 (1998) 660-663
104. Minghetti L. Cyclooxygenase-2 (COX-2) in inflammatory and degenerative brain diseases. J. Neuropathol. Exp. Neurol. 63 (2004) 901-910
105. Nagano S., Huang X., Moir R.D., Payton S.M., Tanzi R.E., and Bush A.I. Peroxidase activity of cyclooxygenase-2 (COX-2) cross-links β-amyloid (Aβ) and generates Aβ-COX-2 hetero-oligomers that are increased in Alzheimer's disease. J. Biol. Chem. 279 (2004) 14673-14678
106. Nathan C., Calingasan N., Nezezon J., Ding A., Lucia M.S., La Perle K., Fuortes M., Lin M., Ehrt S., Kwon N.S., Chen J., Vodovotz Y., Kipiani K., and Beal M.F. J. Exp. Med. 202 (2005) 1163-1169
107. Nishiyama K., Murayama S., Shimizu J., Ohya Y., Kwak S., Asayama K., and Kanazawa I. Cu/Zn superoxide dismutase-like immunoreactivity is present in Lewy bodies from Parkinson disease: a light and electron microscopic immunocytochemical study. Acta Neuropathol. 89 (1995) 471-474
108. Pennathur S., Jackson-Lewis V., Przedborski S., and Heinecke J.W. Mass spectrometric quantification of 3-nitrotyrosine, ortho-tyrosine, and o,o-dityrosine in brain tissue of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice, a model of oxidative stress in Parkinson's disease. J. Biol. Chem. 274 (1999) 34621-34628
109. Perier C., Tieu K., Guegan C., Caspersen C., Jackson-Lewis V., Carelli V., Martinuzzi A., Hirano M., Przedborski S., and Vila M. Complex I deficiency primes Bax-dependent neuronal apoptosis through mitochondrial oxidative damage. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 19126-19131
110. Perluigi M., Poon H.F., Hensley K., Pierce W.M., Klein J.B., Calabrese V., De Marco C., and Butterfield D.A. Proteomic analysis of 4-hydroxy-2-nonenal-modified proteins in G93A-SOD1 transgenic mice-a model of familial amyotrophic lateral sclerosis. Free Radic. Biol. Med. 38 (2005) 960-968
111. Poon H.F., Frasier M., Shreve N., Calabrese V., Wolozin B., and Butterfield D.A. Mitochondrial associated metabolic proteins are selectively oxidized in A30P alpha-synuclein transgenic mice-a model of familial Parkinson's disease. Neurobiol. Dis. 18 (2005) 492-498
112. Poon H.F., Hensley K., Thongboonkerd V., Merchant M.L., Lynn B.C., Pierce W.M., Klein J.B., Calabrese V., and Butterfield D.A. Redox proteomics analysis of oxidatively modified proteins in G93A-SOD1 transgenic mice-a model of amyotrophic lateral sclerosis. Free Radic. Biol. Med. 39 (2005) 453-462
113. Qin W., Peng Y., Ksiezak-Reding H., Ho L., Stetka B., Lovati E., and Pasinetti G.M. Inhibition of cyclooxygenase as potential novel therapeutic strategy in N1411 presenilin-2 familial Alzheimer's disease. Mol. Psychiatry 11 (2006) 172-181
114. Radi R. Nitric oxide, oxidants, and protein tyrosine nitration. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 4003-4008
115. Reynolds M.R., Berry R.W., and Binder L.I. Site-specific nitration and oxidative dityrosine bridging of the tau protein by peroxynitrite: implications for Alzheimer's disease. Biochemistry 44 (2005) 1690-1700
116. Ristimaki A. Cyclooxygenase-2: from inflammation to carcinogenesis. Novartis Found Symp. 256 (2004) 215-221
117. Ritchie C.W., Bush A.I., Mackinnon A., Macfarlane S., Mastwyk M., MacGregor L., Kiers L., Cherny R., Li Q.X., Tammer A., Carrington D., Mavros C., Volitakis I., Xilinas M., Ames D., Davis S., Bevreuther K., Tanzi R.E., and Masters C.L. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch. Neurol. 60 (2003) 1685-1991
118. Sargsyan S.A., Monk P.N., and Shaw P.J. Microglia as potential contributors to motor neuron injury in amyotrophic lateral sclerosis. Glia 51 (2005) 241-253
119. Sathasivam S., Grierson A.J., and Shaw P.J. Characterization of the caspase cascade in a cell culture model of SOD1-related familial amyotrophic lateral sclerosis: expression, activation and therapeutic effects of inhibition. Neuropathol. Appl. Neurobiol. 31 (2005) 467-485
120. Sawada H., Kohno R., Kihara T., Izumi Y., Sakka N., Ibi M., Nakanishi M., Nakamizo T., Yamakawa K., Shibasaki H., Yamamoto N., Akaike A., Inden M., Kitamura Y., Taniguchi T., and Shimohama S. Proteasome mediates dopaminergic neuronal degeneration, and its inhibition causes alpha-synuclein inclusions. J. Biol. Chem. 279 (2004) 10710-10719
121. Sayre L.M., Perry G., Atwood C.S., and Smith M.A. The role of metals in neurodegenerative diseases. Cell Mol. Biol. 46 (2000) 731-741
122. Schiess M. Non-steroidal anti-inflammatory drugs protect against Parkinson neurodegeneration. Arch. Neurol. 60 (2003) 1043-1044
123. Schopfer F.J., Baker P.R., and Freeman B.A. NO-dependent protein nitration: a cell signaling event or an oxidative inflammatory response?. Trends Biochem. Sci. 28 (2003) 646-654
124. Schulz J.B., Matthews R.T., Klockgether T., Dichgans J., and Beal M.F. The role of mitochondrial dysfunction and neuronal nitric oxide in animal models of neurodegenerative diseases. Mol. Cell Biochem. 174 (1997) 193-197
125. Shults C.W. Lewy bodies. Proc. Natl. Acad. Sci. U.S.A. 103 (2006) 1661-1668
126. Sian J., Dexter D.T., Lees A.J., Daniel S., Agid Y., Javoy-Agid F., Jenner P., and Marsden C.D. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann. Neurol. 36 (1994) 348-355
127. Simmons D.L., Botting R.M., and Hla T. Cyclooxygenase isoenzymes: the biology of prostaglandin synthesis and inhibition. Pharmacol. Rev. 56 (2004) 387-437
128. Smith M.A., Richie Harris P.L., Sayre L.M., Beckman J.S., and Perry G. Widespread peroxynitrite-mediated damage in Alzheimer's disease. J. Neurosci. 17 (1997) 2653-2657
129. Smith D.P., Ciccotosto G.D., Tew D.J., Fodero-Tavoletti M.T., Johanssen T., Masters C.L., Barnham K.J., and Cappai R. Concentration dependent Cu2+ induced aggregation and dityrosine formation of the Alzheimer's disease amyloid-beta peptide. Biochemistry 46 (2007) 2881-2891
130. Sonsalla P.K., and Heikkila R.E. The influence of dose and dosing interval on MPTP-induced dopaminergic neurotoxicity in mice. Eur. J. Pharmacol. 129 (1986) 339-345
131. Sriram K., Pai K.S., Boyd M.R., and Ravindranath V. Evidence for generation of oxidative stress in brain by MPTP: in vitro and in vivo studies in mice. Brain Res. 749 (1997) 44-52
132. Strausak D., Mercer J.F., Dieter H.H., Stremmel W., and Multhaup G. Copper in disorders with neurological symptoms: Alzheimer's, Menkes, and Wilson diseases. Brain Res. Bull. 55 (2001) 175-185
133. Strong M.J., Kesavapany S., and Pant H.C. The pathobiology of amyotrophic lateral sclerosis: a proteinopathy?. J. Neuropathol. Exp. Neurol. 64 (2005) 649-664
134. Tamagno E., Parola M., Guglielmotto M., Santoro G., Bardini P., Marra L., Tabaton M., and Danni O. Multiple signaling events in amyloid beta-induced, oxidative stress-dependent neuronal apoptosis. Free Radic. Biol. Med. 35 (2003) 45-58
135. Teismann P., and Ferger B. Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson's disease. Synapse 39 (2001) 167-174
136. Teismann P., Tieu K., Choi D.-K., Wu D.-C., Naini A., Hunot S., Vila M., Jackson-Lewis V., and Przedborski S. Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 5473-5478
137. Teismann P., Vila M., Choi D.-K., Tieu K., Wu D.-C., Jackson-Lewis V., and Przedborski S. COX-2 and neurodegeneration in Parkinson's disease. Ann. N Y Acad. Sci. 991 (2003) 272-277
138. Tieu K., Ischiropoulos H., and Przedborski S. Nitric oxide and reactive oxygen species in Parkinson's disease. IUBMB Life 55 (2003) 329-335
139. Trieu V.N., Liu R., Liu X.P., and Uckun F.M. A specific inhibitor of janus kinase-3 increases survival in a transgenic mouse model of amyotrophic lateral sclerosis. Biochem. Biophys. Res. Commun. 267 (2000) 22-25
140. Valderrama B., Avala M., and Vazquez-Duhalt R. Suicide inactivation of peroxidases and the challenge of engineering more robust enzymes. Chem. Biol. 9 (2002) 555-565
141. Van den Bosch L., Tilkin P., Lemmens G., and Robberecht W. Minocyclin delaysdisease onset and mortality in a transgenic mouse model of ALS. Neuroreport 13 (2002) 1067-1070
142. Vlasova I.I., Tyurin V.A., Kapralov A.A., Kurnikov I.V., Osipov A.N., Potapovich M.V., Stovanovsky D.A., and Kagan V.E. Nitric oxide inhibits peroxidase activity of cytochrome c.cardiolipin complex and blocks cardiolipin oxidation. J. Biol. Chem. 281 (2006) 14554-14562
143. +-induced COX-2 activation and subsquent dopaminergic neurodegeneration. FASEB J. 19 (2005) 1134-1136
144. Webster B., Hansen L., Adame A., Crews L., Torrance M., Thal L., and Masliah E. Astroglial activation of extracellular-regulated kinase in early stages of Alzheimer disease. J. Neuropathol. Exp. Neurol. 65 (2006) 142-151
145. Wiedau-Pazos M., Goto J.J., Rabizadeh S., Gralla E.B., Roe J.A., Lee M.K., Valentine J.S., and Bredesen D.E. Altered reactivity of superoxide dismutase in familial amyotrophic lateral sclerosis. Science 271 (1996) 515-518
146. Wilkinson B.L., and Landreth G.E. The microglial NADPH oxidase complex as a source of oxidative stress in Alzheimer's disease. Neuroinflammation 3 (2006) 30
147. Woodhouse A., Vickers J.C., and Dickson T.C. Cytoplasmic cytochrome c immunolabelling in dystrophic neurites in Alzheimer's disease. Acta Neuropathol. 112 (2006) 429-437
148. + toxicity in vivo. Ann. N Y Acad. Sci. 899 (2000) 255-261
149. Xu Z., Jung C., Higgins C., Levine J., and Kong J. Mitochondrial degeneration in amyotrophic lateral sclerosis. J. Bioenerg. Biomembr. 36 (2004) 395-399
150. Yim M.B., Kang J.-H., Yim H.-S., Kwak H.-S., Chock P.B., and Stadtman E.R. A gain-of-function of an amyotrophic lateral sclerosis-associated Cu,Zn-superoxide dismutase mutant: an enhancement of free radical formation due to a decrease in Km for hydrogen peroxide. Proc. Natl. Acad. Sci. 93 (1996) 5709-5714
151. Yim H.S., Kang J.H., Chock P.B., Stadtman E.R., and Yim M.B. A familial amyotrophic lateral sclerosis-associated A4 V Cu,Zn-superoxide dismutase mutant has a lower Km for hydrogen peroxide. Correlation between clinical severity and the Km value. J. Biol. Chem. 272 (1997) 8861-8863
152. Yim M.B., Yim H.S., Chock P.B., and Stadtman E.R. Enhanced free radical generation of FALS-associated Cu,Zn-SOD mutants. Neurotox. Res. 1 (1999) 91-97
153. Youdim M.B.H., Grünblatt E., and Mandel S. The pivotal role of iron in NF-κB activation and nigrostriatal dopaminergic neurodegeneration. Ann. N Y Acad. Sci. 890 (1999) 7-25
154. Zhang H., Joseph J., Gurney M., Becker D., and Kalyanaraman B. Bicarbonate enhances peroxidase activity of Cu,Zn-superoxide dismutase. Role of carbonate anion radical and scavenging of carbonate anion radical by metalloporphyrin antioxidant enzyme mimetics. J. Biol. Chem. 277 (2002) 1013-1020
155. Zhang H., Andrekopoulos C., Joseph J., Chandran K., Karoui H., Crow J.P., and Kalyanaraman B. Bicarbonate-dependent peroxidase activity of human Cu,Zn-superoxide dismutase induces covalent aggregation of protein: intermediacy of tryptophan-derived oxidation products. J. Biol. Chem. 278 (2003) 24078-24089
156. Zhang W., Wang T., Pei Z., Miller D.S., Wu X., Block M.L., Wilson B., Zhang W., Zhou Y., Hong J.S., and Zhang J. Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease. FASEB J. 19 (2005) 533-542
157. Zhou Y., Wang Y., Kovacs M., and Zhang J. Microglial activation induced by neurodegeneration: a proteomic analysis. Mol. Cell Proteomics 4 (2005) 1471-1479
158. Zhu S., Stavrovskaya I.G., Drozda M., Kim B.Y., Ona V., Li M., Sarang S., Liu A.S., Hartley D.M., Wu du C., Gullans S., Ferrante R.J., Przedborski S., Krystal B.S., and Friedlander R.M. Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature 417 (2002) 74-78
159. Zhu X., Smith M.A., Perry G., and Aliev G. Mitochondrial failures in Alzheimer's disease. Am. J. Alzheimers Dis. Other Dem. 19 (2004) 345-352
160. Zhu X., Lee H., Moreira P.I., Smith M.A., and Perry G. Presenilin mutation: a deadly first hit in Alzheimer disease. Free Radic. Biol. Med. 40 (2006) 737-739
161. Zielasek J., Tausch M., Toyka K.V., and Hartung H.P. Production of nitrite by neonatal rat microglial cells/brain macrophages. Cell Immunol. 141 (1992) 111-120
162. + neurotoxicity and delays its elimination from the striatum. Brain Res. 501 (1989) 11-22